111 Stock Forecast, Price & News

+0.34 (+3.76 %)
(As of 06/18/2021 04:50 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume279,874 shs
Average Volume850,224 shs
Market Capitalization$776.34 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive YI News and Ratings via Email

Sign-up to receive the latest news and ratings for 111 and its competitors with MarketBeat's FREE daily newsletter.

About 111

111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. Its product portfolio comprises prescription and over-the counter drugs, such as western and traditional Chinese medicinal drugs; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices, including bandages and thermometers; and personal care products, such as skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Drug Mall, including pharmacies and wholesalers; and digital contract sales organization and data services. As of December 31, 2020, it operated 13 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Wuhan, Tianjin, and Kunshan. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. 111, Inc. has strategic partnerships with Bayer Healthcare Co. Ltd.; BeiGene, Ltd.; and Jianming Pharmaceutical Group. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.14 out of 5 stars

Medical Sector

1021st out of 2,100 stocks

Drug Stores & Proprietary Stores Industry

6th out of 14 stocks

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

111 (NASDAQ:YI) Frequently Asked Questions

Is 111 a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 111 in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" 111 stock.
View analyst ratings for 111
or view top-rated stocks.

What stocks does MarketBeat like better than 111?

Wall Street analysts have given 111 a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 111 wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting 111?

111 saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 901,700 shares, an increase of 21.4% from the May 13th total of 743,000 shares. Based on an average daily volume of 513,200 shares, the short-interest ratio is presently 1.8 days.
View 111's Short Interest

When is 111's next earnings date?

111 is scheduled to release its next quarterly earnings announcement on Thursday, August 19th 2021.
View our earnings forecast for 111

How has 111's stock been impacted by COVID-19 (Coronavirus)?

111's stock was trading at $6.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, YI stock has increased by 43.4% and is now trading at $9.39.
View which stocks have been most impacted by COVID-19

What guidance has 111 issued on next quarter's earnings?

111 issued an update on its second quarter 2021 earnings guidance on Tuesday, June, 15th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $445.68 million-470.10 million.

What price target have analysts set for YI?

1 equities research analysts have issued 12 month price objectives for 111's stock. Their forecasts range from $16.00 to $16.00. On average, they expect 111's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 70.4% from the stock's current price.
View analysts' price targets for 111
or view top-rated stocks among Wall Street analysts.

Who are 111's key executives?

111's management team includes the following people:
  • Dr. Gang Yu, Co-Founder & Exec. Chairman (Age 62)
  • Mr. Junling Liu, Co-Founder, Acting CFO, Chairman & CEO (Age 56)
  • Mr. Haihui Wang, Co-Chief Operating Officer
  • Mr. Pengcheng Zhu, Co-Chief Operating Officer
  • Monica Mu, IR Director
  • Mr. Anfeng Guo, Chief Innovation Officer
  • Mr. Alex Liu, Fin. Director

Who are some of 111's key competitors?

What other stocks do shareholders of 111 own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 111 investors own include AbbVie (ABBV), Gilead Sciences (GILD), El Pollo Loco (LOCO), Noodles & Company (NDLS), (NOVA), (NVST), Pfizer (PFE), Revolve Group (RVLV), Soleno Therapeutics (SLNO) and Chanticleer (BURG).

When did 111 IPO?

(YI) raised $140 million in an initial public offering on Wednesday, September 12th 2018. The company issued 9,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup and CICC acted as the underwriters for the IPO.

What is 111's stock symbol?

111 trades on the NASDAQ under the ticker symbol "YI."

Who are 111's major shareholders?

111's stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (0.94%), Jane Street Group LLC (0.80%), JPMorgan Chase & Co. (0.42%), Canada Pension Plan Investment Board (0.35%), Renaissance Technologies LLC (0.30%) and BlackRock Inc. (0.28%).

Which major investors are selling 111 stock?

YI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Credit Suisse AG.

Which major investors are buying 111 stock?

YI stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Jane Street Group LLC, JPMorgan Chase & Co., Canada Pension Plan Investment Board, Alliancebernstein L.P., Bellevue Group AG, Nuveen Asset Management LLC, and Citadel Advisors LLC.

How do I buy shares of 111?

Shares of YI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 111's stock price today?

One share of YI stock can currently be purchased for approximately $9.39.

How much money does 111 make?

111 has a market capitalization of $776.34 million and generates $1.26 billion in revenue each year.

How many employees does 111 have?

111 employs 2,189 workers across the globe.

What is 111's official website?

The official website for 111 is

Where are 111's headquarters?

111 is headquartered at 3-5/F NO.295 ZUCHONGZHI ROAD PUDONG NEW AREA, SHANGHAI F4, 201203.

How can I contact 111?

111's mailing address is 3-5/F NO.295 ZUCHONGZHI ROAD PUDONG NEW AREA, SHANGHAI F4, 201203. The company can be reached via phone at 862120536666.

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.